Clinical Trial

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Study acronym: LEADER-PAD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-02-24; most recent amendment 2026-03-20.
Status change: Not Yet Recruiting → Recruiting 2021-09-14
Trial Details
NCT Number NCT04774159
Lead Sponsor Population Health Research Institute
Conditions Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Enrollment 6,150 participants
Start Date 2021-05-06
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-24